Target | (1R,2S)-Fluorocyclopropylamine Tosylate |
Purity | 0.97 |
CAS Number | 143062-84-4 |
SMILES | CC1=CC=C(C=C1)S(O)(=O)=O.N[C@@H]1C[C@@H]1F |
UNSPSC Code | 41116105 |
Availability | Shipped within 1-2 weeks. |
Note | This product is for research use only. |
Abbexa是一家致力于为生命科学研究、药物研发及生物技术公司提供优质抗体、蛋白及检测试剂盒等产品的高科技生物技术公司。基于剑桥大学研发技术优势,Abbexa提供包括一抗、二抗、纯化蛋白、ELISA试剂盒、各种酶类及其它多种试剂与研究工具的大量生命科学研究产品。
目前Abbexa的产品涵盖单克隆抗体、多克隆抗体、纯化蛋白质及生物试剂,此外,为满足研发人员特殊的实验需要,Abbexa还提供抗体/多肽定制服务。严格的质控标准保证了Abbex产品的高性能,如您对产品不满意,Abbexa将直接提供退/换货服务
CLIAKits 化学发光免疫分析(chemiluminescenceimmunoassay,CLIA) RNAInterferenceProducts RNA干扰试剂 RNA干扰(RNAinterference,RNAi)是指在进化过程中高度保守的、由双链RNA(double-strandedRNA,dsRNA)诱发的、同源mRNA高效特异性降解的现象。基因沉默,主要有转录前水平的基因沉默(TGS)和转录后水平的基因沉默(PTGS)两类:TGS是指由于DNA修饰或染色体异染色质化等原因使基因不能正常转录;PTGS是启动了细胞质内靶mRNA序列特异性的降解机制。有时转基因会同时导致TGS和PTGS。 由于使用RNAi技术可以特异性剔除或关闭特定基因的表达,(长度超过三十的dsRNA会引起干扰素毒性)所以该技术已被广泛用于探索基因功能和传染性疾病及恶性肿瘤的治疗领域。 1. RNAi抑制转座子活性 两方面的证据提示转座子活性的抑制与siRNA有关 ①发现蠕虫mut-7基因参与RNAi并且与转座子的转座抑制有关; ②在果蝇中,参与RNAi的RNA解螺旋酶Spindle-E的突变将导致该基因引起的基因沉默的缺失,同时提高了反转录转座子活性。 2. RNAi抵御病毒感染 在拟南芥中研究转基因引起基因沉默时发现,sgs2/sde1基因突变的拟南芥对病毒的侵染表现出高度的敏感性。 3. RNAi参与异染色质的形成和维持 Hall等研究表明,着丝粒同源重复序列和RNAi组分一起正负调节着异染色质的形成并共同促使异染色质组装成核;Vople等在敲除裂殖酵母(S.pombe)的RNAi途径基因(如Argonaute、Dicer、RDRP)时发现异染色质转录得到的dsRNA可以在RNAi途径的参与下,加工成siRNA,siRNA募集异染色质蛋白1(HP1),然后靶向性引起相应异染色质区域的转基因沉默。 4. RNAi参与机体的发育调控及生理代谢 RNAi只抑制转录后的基因,所以RNAi在生物体发育学研究中具有优势。Chuang等用RNAi技术进一步证实了AG、CLV3、AP1、PAN等已知功能基因在拟南芥花发育过程中的功能。在RNAi过程中形成的RISC复合物可根据不同情况分别利用siRNA或stRNA行使不同的功能,但最终均导致特定基因沉默。 IsotypeControl 同型对照 同型对照(IsotypeControl),使用与一抗相同种属来源、相同亚型、相同剂量和相同的免疫球蛋白及亚型的免疫球蛋白,用于消除由于抗体非特异性结合到细胞表面而产生的背景染色。 同型对照 同型对照的主要目的是确定一抗的结合是特异性的,而不是非特异性的Fc受体或与其他蛋白的相互作用。还可以用来竞争性的结合抗体,与功能阻断抗体发挥同样的功能。 同型对照要与一抗的来源,Ig分型和标记完全一致。 如果一抗是多抗,可以用annormalserum(与一抗相同的正常血清)(mustbethesamespeciesasprimaryantibody)。Thiscontroliseasytoachieveandcanbeusedroutinelyinimmunohistochemicalstaining.这个可以咨询试剂商。同型对照为免疫荧光标记中的阴性对照。由于荧光标记单抗的组来源不同,应选用相同来源的未标记单抗作为同型对照来调整背景染色。举个例子:比如检测一抗为单抗的mouseantiratCD11b,cloneOX-42purifiedIgG,那么它的isotype是mouseIgG2a,所以可以用purified(纯化的)mouseIgG2a来做OX-42的同型对照(IsotypeControl)。一般的的生物技术公司和国内的代理都有出售。 同型对照:是指与MoAb相同的、未免疫小鼠的免疫球蛋白亚类,若使用直接免疫荧光染色法,同型对照也应标记荧光色素,如IgG1FITC、IgG2a、PE等。主要考虑了细胞的自发荧光、FC受体介导的抗体结合和非特异性抗体结合等影响因素。此外,同型对照与MoAb所标记的荧光色素、浓度、F:P比值(标记的荧光色素与免疫球蛋白分子的比值)应该相同为最佳,这对准确设定阴性与阳性细胞的界标有重要意义,切忌使用与MoAb不相匹配的同型对照,最好为同一实验室、采用相同工艺或方法制备(如同一品牌)的产品。
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
果糖胺是血浆中的蛋白质与葡萄糖非酶糖化过程中形成的高分子酮胺结构类似果糖胺的物质,它的浓度与血糖水平成正相关,并相对保持稳定。它的测定却不受血糖的影响。由于血浆蛋白的半衰期为17~20天,故果糖胺可以反映糖尿病患者检测前1~3周内的平均血糖水平。从一定程度上弥补了糖化血红蛋白不能反映较短时期内血糖浓度变化的不足。果糖胺的测定快速而价廉(化学法),是评价糖尿病控制情况的一个良好指标,尤其是对血糖波动较大的脆性糖尿病及妊娠糖尿病,了解其平均血糖水平有实际意义。但果糖胺不受每次进食的影响,所以不能用来直接指导每日胰岛素及口服降糖药的用量。血清果糖胺正常值为1.64~2.64mmol/L,血浆中果糖胺较血清低0.3mmol/L。
名称:氨氧基乙酸盐;羧甲氧基胺半盐酸盐;
分子式:C2H5NO3·0.5HCl
分子质量:109.30
熔点:156℃
【认领须知】
1、认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他战友认领!”
2、请根据自己专业背景选择认领,如使用翻译软件翻译,被发现者扣分1-2分
3、经常认领而不能及时提供优质稿件者将被列入黑名单,取消认领资格,请大家注意!
4、翻译时请参照版规:点击查看互
5、在首位认领战友未超过规定时间的其他任何认领属违规认领,将不会给予丁当或加分!
6、翻译完成后加分(或丁当)的时限为三日,请耐心等待,若超过时限未加者可进行申诉:点击进入
7、本文题目仅供译者参考,篇幅较长者可申请适当延时
8、翻译前请查一下有无重复帖
9、为保证翻译质量,每人每天最多只能认领两篇
10、链接:http://www.ascopost.com/News/57763
ICML2017:PhaseIIIbMAGNIFYStudyofLenalidomideandRituximabCombinationinRelapsed/RefractoryFollicularandMarginalZoneLymphoma
AninterimanalysisofMAGNIFY,aphaseIIIb,randomized,open-label,multicenterstudyoftheR2combinationregimen(lenalidomide[Revlimid]plusrituximab[Rituxan])inpatientswithrelapsedorrefractorymarginalzonelymphoma,waspresentedattheInternationalConferenceonMalignantLymphoma(ICML)inLugano,Switzerland.ThisanalysisexpandedupondatapresentedearlierinthemonthattheASCOAnnualMeeting(Abstract7502).
TheMAGNIFYstudycontinuestoevaluatetheclinicalactivityof12cyclesofR2combinationtherapyfollowedbyrandomizationtoeither18cyclesofR2maintenanceor18cyclesofrituximabmonotherapy,inpatientswithrelapsedorrefractoryfollicularlymphoma,marginalzonelymphoma,ormantlecelllymphoma.Approximately500patientsareplannedtobeenrolledinthestudy.
Theprimaryendpointisprogression-freesurvival.Secondaryendpointsincludeoverallsurvival,overallresponserate,completeresponse,improvementofresponse,durationofresponse,durationofcompleteresponse,timetonextlymphomatreatment,timetohistologictransformation,safety,andexploratoryquality-of-lifemeasures.EnrollmentintheMAGNIFYstudyisongoing.
ASCOData
AttheASCOAnnualMeeting,interimdatawerepresentedfromananalysisofasubsetofpatientsfromtheMAGNIFYstudywithrelapsedorrefractoryfollicularlymphoma(n=160)withearly-relapse(n=52)anddouble-refractory(n=50)disease.
AttheJanuary9,2017,datacutoff,the1-yearprogression-freesurvivalforallfollicularlymphomapatientswas70%,with65%fordouble-refractorypatientsand49%forearly-relapsepatients.Additionally,evaluablefollicularlymphomapatients(n=128)hadanoverallresponserateof66%withacompleteresponse/completeresponse–unconfirmedrateof38%.Fordouble-refractorypatients(n=42),overallresponseratewas45%withacompleteresponse/completeresponse–unconfirmedrateof21%andforearly-relapsepatients(n=43),overallresponseratewas47%withacompleteresponse/completeresponse–unconfirmedrateof21%.Mediandurationofresponsewasnotmetatamedianfollow-upof10.2months.
Themostcommongrade3or4adverseeventsobservedinthestudyforallfollicularlymphoma,double-refractory,andearly-relapsepatients,respectively,wereneutropenia(29%,42%,37%),fatigue(6%,4%,8%),leukopenia(5%,8%,10%),thrombocytopenia(4%,8%,4%),andlymphopenia(3%,6%,4%).
ICMLData
DatapresentedatICMLinaseparateanalysisfocusedonpatientswithmarginalzonelymphoma(n=38),includingnodalmarginalzonelymphoma(n=18),splenicmarginalzonelymphoma(n=10),andmucosa-associatedlymphoidtissuelymphoma(n=10).
Atamedianfollow-upof13.8monthsfrominitiationoftherapywiththeR2combination,evaluablepatientswithmarginalzonelymphoma(n=32)achievedanoverallresponserateof66%withacompleteresponse/completeresponse–unconfirmedrateof44%.Evaluablenodalmarginalzonelymphomapatients(n=14)hadanoverallresponserateof57%withacompleteresponse/completeresponse–unconfirmedrateof57%.Evaluablesplenicmarginalzonelymphomapatients(n=8)hadanoverallresponserateof63%withacompleteresponserateof25%;andevaluablemucosa-associatedlymphoidtissuelymphomapatients(n=10)hadanoverallresponserateof80%withacompleteresponse/completeresponse–unconfirmedrateof40%.Mediandurationofresponsewasnotreachedforanygroup.
Themostcommongrade3or4adverseeventsobservedinpatientswithmarginalzonelymphomawereneutropenia(32%),thrombocytopenia(16%),andleukopenia(11%).
“Thechemotherapy-freecombinationoflenalidomideandrituximab,withcomplementarymechanismsofactionthatarethoughttoenhanceantibodydependentcellularcytotoxicity,continuestoshowencouragingactivityandatolerablesafetyprofileinindolentlymphomas,andparticularlyindifficult-to-treatpatientsubsets,”saidDavidJ.Andorsky,MD,co–principalinvestigatorofthestudyandmedicaloncologistattheRockyMountainCancerCentersinBoulder,Colorado.“Theseresultsinpatientswhohadfailedmultipletherapiesorrelapsedearly,aswellastheactivityinmarginalzonepatientsmeritfurtherstudyinthisareaofindolentlymphoma.”
AboutMAGNIFY
MAGNIFYisaphaseIIIb,multicenter,open-labelstudyofpatientswithgrades1–3bortransformedfollicularlymphoma,marginalzonelymphoma,ormantlecelllymphomawhoreceivedatleast1priortherapyandhadstageI–IV,measurabledisease.Approximately500patientsareplannedforenrollmentin12cyclesofR2induction,withaprojected314patientswithatleaststablediseaseafterinductionrandomized(1:1)to2maintenancearms.
Inductionincludesorallenalidomideat20mg/d,days1–21per28-daycycle(d1–21/28)plusintravenousrituximabat375mg/m2,days1,8,15,and22ofcycle1andday1ofcycles3,5,7,9,and11(28-daycycles).Patientsarethenrandomizedtomaintenancelenalidomideat10mg/d,days1to21/28,cycles13to30,plusrituximabat375mg/m2,day1ofcycles13,15,17,19,21,23,25,27,and29(R2,armA),orrituximabalone(sameschedule,armB).PatientsreceivingR2maintenanceafter18cyclesmaycontinuemaintenancelenalidomidemonotherapyat10mg/d,days1–21/28(perpatientand/orinvestigatordiscretion),untildiseaseprogressionastolerated.Patientswillbefollowedfor≥5yearsafterthelastpatientinitiatesinductiontherapy.
【认领须知】
1、认领翻译的战友请跟帖注明“认领本文翻译,48小时内未完成,请其他战友认领!”
2、请根据自己专业背景选择认领,如使用翻译软件翻译,被发现者扣分1-2分
3、经常认领而不能及时提供优质稿件者将被列入黑名单,取消认领资格,请大家注意!
4、翻译时请参照版规:点击查看
5、在首位认领战友未超过规定时间的其他任何认领属违规认领,将不会给予丁当或加分!
6、翻译完成后加分(或丁当)的时限为三日,请耐心等待,若超过时限未加者可进行申诉:点击进入
7、本文题目仅供译者参考,篇幅较长者可申请适当延时
8、翻译前请查一下有无重复帖
9、为保证翻译质量,每人每天最多只能认领两篇
原文链接:http://www.ascopost.com/News/40561
AdditionofIxazomibtoLenalidomide/DexamethasoneImprovesProgression-FreeSurvivalinRelapsed/RefractoryMultipleMyeloma
Moreauetalfoundthataddingtheoralproteasomeinhibitorixazomib(Ninlaro)tolenalidomide(Revlimid)anddexamethasonesignificantlyprolongedprogression-freesurvivalamongpatientswithrelapsed,refractory,orrelapsedandrefractorymultiplemyeloma.TheyreportedthefindingsfromthephaseIIITOURMALINE-MM1trialinTheNewEnglandJournalofMedicine.ThetrialsupportedtherecentU.S.FoodandDrugAdmiNISTration(FDA)approvalofixazomibinpreviouslytreatedmultiplemyeloma,makingitthefirstapprovedoralproteasomeinhibitor.
StudyDetails
Inthedouble-blindtrial,722patientsfrom147sitesin26countrieswererandomizedbetweenAugust2012andMay272014toreceiveixazomib(n=360)orplacebo(n=362)pluslenalidomideanddexamethasone.Treatmentconsistedof28-daycyclesoforalixazomibat4mgorplaceboondays1,8,and15;orallenalidomideat25mgondays1through21(10mginthosewithcreatinineclearance≤60or≤50mL/min/1.73m2accordingtolocalprescribinginformation);andoraldexamethasoneat40mgondays1,8,15,and22.Theprimaryendpointwasprogression-freesurvival.
Fortheixazomibvsplacebogroups,medianagewas66yearsinboth(53%vs51%>65years);58%vs56%weremale;86%vs83%werewhite;EasternCooperativeOncologyGroupperformancestatuswas0or1in95%vs93%;InternationalStagingSystem(ISS)stagewasIin63%vs64%,IIin25%vs24%,andIIIin12%inboth;78%vs72%hadcreatinineclearance≥60mL/min/1.73m2;55%vs60%hadstandard-and21%vs17%hadhigh-riskcytogenetics;numberofpriortherapieswas1in62%vs60%,2in27%vs31%,and3in11%vs9%;59%vs55%hadpriorstemcelltransplantation;diseasecategorywasrelapsedin77%inboth,refractoryin12%vs11%,relapsedandrefractoryin11%vs12%,andprimaryrefractoryin7%vs6%;priorproteasomeinhibitortherapywasbortezomib(Velcade)in69%inbothandcarfilzomib(Kyprolis)in<1%vs1%,with1%vs2%ofpatientshavingdiseaserefractorytopriortreatment;andpriorimmunomodulatorytherapywaslenalidomidein54%vs56%andthalidomide(Thalomid)in44%vs47%,with21%vs25%havingdiseaserefractorytopriortherapy.
ImprovedProgression-FreeSurvival
Aftermedianfollow-upof14.7months,medianprogression-freesurvivalwas20.6monthsintheixazomibgroupvs14.7monthsintheplacebogroup(hazardratio[HR]=0.74,P=.01).Benefitofixazomibwasconsistentacrossprespecifiedsubgroups,includingpoor-prognosissubgroupssuchasthosewithhigh-riskcytogenetics(24.1vs9.7months,HR=0.54),ISSstageIIIdisease(18.4vs10.1months,HR=0.72),thoseaged>75years(18.5vs13.1months,HR=0.87),andthosewhohadreceivedtwo(17.5vs14.1months,HR=0.75)orthree(notestimablevs10.2months,HR=0.37)priortherapies.
Overallresponserateswere78%vs72%,withtheratesofcompleteresponseplusverygoodpartialresponseof48%vs39%.Mediantimetoresponsewas1.1vs1.9months.Mediandurationofresponsewas20.5vs15.0months.Atmedianfollow-upofapproximately23months,medianoverallsurvivalhadnotbeenreachedineithergroup.
AdverseEvents
Adverseeventsof≥grade3occurredin74%oftheixazomibgroupvs69%oftheplacebogroup,withthemostcommonintheixazomibgroupbeingneutropenia(23%vs24%)andthrombocytopenia(19%vs9%).Rashofanygradewasmorecommonintheixazomibgroup(36%vs23%),asweregastrointestinaladverseevents(mostlylowgrade);22%ofixazomibpatientsand19%ofplacebopatientsreceivedantidiarrhealagents,and21%and13%receivedantiemeticdrugs.Peripheralneuropathyofanygradeoccurredin27%vs22%(grade3in2%ineach).
Seriousadverseeventsoccurredin47%vs49%.Adverseeventsledtodosereductionofanydrugin56%vs50%,discontinuationofanydrugin25%vs20%,anddiscontinuationofthestudyregimenin17%vs14%.Deathoccurredduringthestudyperiodin4%vs6%.
Theinvestigatorsconcluded:“Theadditionofixazomibtoaregimenoflenalidomideanddexamethasonewasassociatedwithsignificantlylongerprogression-freesurvival;theadditionaltoxiceffectswiththisall-oralregimenwerelimited.”
暂无品牌问答